Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyThe Future Role of Bispecific Antibodies in Lymphoma

The differences between bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy, the side effects of bispecific antibodies, how the antibodies may address unmet needs in lymphoma, and a few other observations are discussed in this interview with Dr. John N. Allan, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York.